Michael A. Davis

机构：Southwest Research Institute, Malaysian Society of Nephrology · ORCID：0000-0002-5406-4128

发表论文 238 篇 · 总被引 8973 次 · h-index 44

代表论文

• Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus (2021 · Nature Communications · 被引 200)
• Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis (2022 · Nature Cancer · 被引 116)
• LOX-1: A potential driver of cardiovascular risk in SLE patients (2020 · PLoS ONE · 被引 29)
• A C57BL/6 Mouse Model of SARS-CoV-2 Infection Recapitulates Age- and Sex-Based Differences in Human COVID-19 Disease and Recovery (2022 · Vaccines · 被引 28)
• Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus (2022 · Annals of the Rheumatic Diseases · 被引 25)
• Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study (2023 · Frontiers in Oncology · 被引 22)